Kyprolis-Carfilzomib

What is Carfilzomib?

Carfilzomib (Kyprolis) is a chemotherapy medication known as a proteasome inhibitor. It is used to treat relapsed or refractory multiple myeloma. Carfilzomib selectively and quite potently, inhibits the “20S” proteasome causing cell death.

How it is administered:

Carfilzomib is administered as an intravenous infusion over 10 minutes. During the first several infusions, additional fluids for hydration will be administered before and after (if needed) each dose of carfilzomib. In order to reduce the occurrence of a hypersensitivity reaction as well as nausea, pre-medications will be administered prior to the infusion. Some regimens require the pre-medication be taken orally instead of intravenously.

What to expect:

Carfilzomib can cause anemia and reduce the body’s ability to fight infections. Additional side effects include, but are not limited to: water retention, fatigue, headache, insomnia, chills, electrolyte imbalances, nausea, diarrhea, constipation, loss of appetite, vomiting, increased liver enzymes, back pain, muscle spasms, joint pain, decreased kidney function, shortness of breath, upper respiratory tract infection, heart tissue damage and herpes zoster reactivation. Additionally, it can cause numbness, pain and tingling in the extremities. It is important to report any changes in feelings of the extremities to your provider immediately. Laboratory tests will be performed routinely throughout the course of therapy to help manage and monitor the development of these side effects.